KCT0004837尚未招募未知
Evaluation of the Effectiveness of Terazosin in Patients with Nocturia due to Prostate Hyperplasia
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- Male
入选标准
- •1. An adult male over 19 years of age
- •2. Persons with an IPSS total score of 8 or higher
- •3. Persons with a maximum urinary speed (Qmax) of less than 15mL/s
- •4. Persons with a single urinary volume of 150 mL or higher
- •5. Persons with more than one night urination
- •6. Those who have agreed to participate in this research under the signature of their own handwriting
排除标准
- •1. Those who are overreacting to Alpha-Blocker drugs
- •2. Person with bladder neck stenosis and urinary tract stenosis
- •3. Persons with renal dysfunction (Creatine concentration in the serum >2.0 mg/dL)
- •4. A person with severe liver failure or with a history of illness.
- •5. Those with severe cardiovascular disease
- •6. A person with severe low blood pressure
- •7. Other persons who are not qualified to participate in this study as the Director of Research judges
研究者
相似试验
尚未招募
不适用
Evaluation of efficacy and safety of terazosin in patients with benign prostatic hyperplasia with lower urinary tract symptomsKCT0005278Yonsei University, Wonju Severance Christian Hospital174
尚未招募
不适用
Efficacy and Safety of Terazosin 4mg in patients with Benign Prostataic Hyperplasia assciated with Chronic Prostatitis/Chronic Pelvic Pain SyndromeKCT0004249Hallym University Medical Center200
尚未招募
不适用
A cross-over study of the effects of terazosin or tamsulosin on the efficacy and sexual function of lower urinary tract symptoms in patients with benign prostatic hyperplasiaDiseases of The genitoruinary systemKCT0004914lsan Univeristy Hospital76
已完成
3 期
The effect of Terazosin and Tolterodine in the treatment of double J stent-related urinary symptomsIRCT20160924029935N2Mashhad University of Medical Sciences80
招募中
3 期
Clinical evaluation of Diabepal tablet in comparison with Placebo tablet in Type 2 Diabetic PatientsCTRI/2014/10/005076Arjun Healthcare80